secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001683168-25-000274
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio reports 2 complete responses in PH-762 Phase 1b second cohort for cutaneous squamous cell carcinoma
--------------------------------------------------------------------------------

- 2 of 4 patients in 2nd cohort achieved 100% tumor clearance (complete response).
- 1 patient had 90% tumor clearance (partial response); 1 had stable disease.
- No dose-limiting toxicities or clinically relevant adverse events reported.
- INTASYL siRNA gene silencing therapy PH-762 is being evaluated in NCT 06014086.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825000274/0001683168-25-000274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825000274/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-000274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer